The FDA's Definitions, Designations, and Drug Approvals: Too Daring?

The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(18)30115-7
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Analysis of Orphan Drug Designations and Approvals in the United States and the European Union

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

FDA's Counsel Accused of Being Too Close to Drug Industry

BMJ
2004English

2017 FDA Drug Approvals

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2018English

Access Before Evidence and the Price of FDA's New Drug Authorities

SSRN Electronic Journal
2019English

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration

JAMA network open
Medicine
2019English

Orphan Drug Approvals in Europe: Historical Review and Trends

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

FDAs Jumpstart Program: A Vital Tool to Accelerate Drug Approvals

International Journal of ChemTech Research
ChemistryChemical Engineering
2018English

Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Latest Orphan Drug Designations and the Commission Communication on Regulation (EC) 141/2000

Journal of Commercial Biotechnology
BiotechnologyManagement of TechnologyEconomicsEconometricsInnovation
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy